Breast Cancer-Therapeutic Challenges, Research Strategies and Novel Diagnostics
Thanks to the breast cancer research of recent decades, effective methods and strategies have been established, allowing the mortality rates of breast cancer patients to decrease more and more. However, we still face many challenges. The role of certain biomarkers or mutations is still not clear for...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_128830 | ||
| 005 | 20231130 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20231130s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-9442-2 | ||
| 020 | |a 9783036594439 | ||
| 020 | |a 9783036594422 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-9442-2 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Nabieva, Naiba |4 edt | |
| 700 | 1 | |a Nabieva, Naiba |4 oth | |
| 245 | 1 | 0 | |a Breast Cancer-Therapeutic Challenges, Research Strategies and Novel Diagnostics |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (282 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Thanks to the breast cancer research of recent decades, effective methods and strategies have been established, allowing the mortality rates of breast cancer patients to decrease more and more. However, we still face many challenges. The role of certain biomarkers or mutations is still not clear for treatment and surveillance. Novel drugs are often associated with a different spectrum of adverse events than that seen for conventional therapies, accordingly having an impact on patients' compliance behaviors. In breast cancer surgery, in some cases, the question remains whether to escalate or deescalate. Additionally, with regard to diagnostics, in a digitalized world, home-based tools and therapy monitoring options are of high importance, especially under the tough conditions and supply problems seen during the COVID-19 pandemic.This Special Issue gathers original research articles and reviews demonstrating therapeutic challenges, current research strategies, and novel diagnostics in breast cancer. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a pannexin 1 (PANX1) | ||
| 653 | |a neutrophils | ||
| 653 | |a adenosine | ||
| 653 | |a tumor microenvironment (TME) | ||
| 653 | |a breast cancer | ||
| 653 | |a ER heterogeneity | ||
| 653 | |a 18F-FES PET/CT | ||
| 653 | |a diagnosis | ||
| 653 | |a treatment pattern | ||
| 653 | |a metastatic breast cancer | ||
| 653 | |a heterogeneity | ||
| 653 | |a HER2 | ||
| 653 | |a 18F-fluorodeoxyglucose positron emission tomography/computed tomography | ||
| 653 | |a pyrotinib | ||
| 653 | |a therapy response | ||
| 653 | |a oncotype DX | ||
| 653 | |a recurrence score | ||
| 653 | |a individualized therapy | ||
| 653 | |a advanced breast cancer | ||
| 653 | |a breast cancer susceptibility genes 1 and 2 | ||
| 653 | |a genetic testing | ||
| 653 | |a human epidermal growth factor receptor 2-negative | ||
| 653 | |a poly(adenosine diphosphate-ribose) polymerase inhibitors | ||
| 653 | |a real-world | ||
| 653 | |a machine learning | ||
| 653 | |a neoadjuvant systemic treatment | ||
| 653 | |a lymph node metastasis | ||
| 653 | |a phytochemicals | ||
| 653 | |a nanocarriers | ||
| 653 | |a chemotherapy | ||
| 653 | |a drug resistance | ||
| 653 | |a risk prediction models | ||
| 653 | |a breast cancer screening | ||
| 653 | |a risk assessment | ||
| 653 | |a risk-based screening | ||
| 653 | |a localization technique | ||
| 653 | |a non-palpable lesion | ||
| 653 | |a intraoperative ultrasound | ||
| 653 | |a wire-guided localization | ||
| 653 | |a magnetic seed | ||
| 653 | |a radioactive seed | ||
| 653 | |a radar reflector | ||
| 653 | |a radiofrequency identification tag | ||
| 653 | |a oncology | ||
| 653 | |a telemedicine | ||
| 653 | |a telerehabilitation | ||
| 653 | |a psychological well-being | ||
| 653 | |a cognitive impairment | ||
| 653 | |a rehabilitation | ||
| 653 | |a cancer side effects | ||
| 653 | |a metastasis | ||
| 653 | |a treatment | ||
| 653 | |a human epidermal growth factor receptor 2 | ||
| 653 | |a hormone receptor | ||
| 653 | |a registries | ||
| 653 | |a endocrine treatment | ||
| 653 | |a CDK4/6 inhibitor | ||
| 653 | |a abemaciclib | ||
| 653 | |a dalpiciclib | ||
| 653 | |a palbociclib | ||
| 653 | |a ribociclib | ||
| 653 | |a Contrast-Enhanced Mammography | ||
| 653 | |a Digital Breast Tomosynthesis | ||
| 653 | |a Average Glandular Dose | ||
| 653 | |a TNBC | ||
| 653 | |a LEMD1 | ||
| 653 | |a ERK | ||
| 653 | |a therapeutic target | ||
| 653 | |a BOUNCE | ||
| 653 | |a coping self-efficacy | ||
| 653 | |a fear of cancer recurrence | ||
| 653 | |a latent growth modeling | ||
| 653 | |a trajectories | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/8299 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/128830 |7 0 |z DOAB: description of the publication |